Cargando…

The role of dendritic cells for therapy of B-cell lymphoma with immune checkpoint inhibitors

Immune checkpoint blocking (ICB) is a promising new tool of cancer treatment. Yet, the underlying therapeutic mechanisms are not fully understood. Here we investigated the role of dendritic cells (DCs) for the therapeutic effect of ICB in a λ-MYC-transgenic mouse model of endogenously arising B-cell...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scheuerpflug, Anne, Ahmetlić, Fatima, Bauer, Vera, Riedel, Tanja, Röcken, Martin, Mocikat, Ralph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053142/ https://www.ncbi.nlm.nih.gov/pubmed/33141285 http://dx.doi.org/10.1007/s00262-020-02767-6

Ejemplares similares

Immune checkpoint blockade impairs immunosuppressive mechanisms of regulatory T cells in B-cell lymphoma
por: Bauer, Vera, et al.
Publicado: (2021)

Therapy of lymphoma by immune checkpoint inhibitors: the role of T cells, NK cells and cytokine-induced tumor senescence
por: Ahmetlic, Fatima, et al.
Publicado: (2021)

Specific targeting of whole lymphoma cells to dendritic cells ex vivo provides a potent antitumor vaccine
por: Adam, Christian, et al.
Publicado: (2007)

Immune-Checkpoint Inhibitors in B-Cell Lymphoma
por: Armengol, Marc, et al.
Publicado: (2021)

Potent CD4(+) T cell-associated antitumor memory responses induced by trifunctional bispecific antibodies in combination with immune checkpoint inhibition
por: Deppisch, Nina, et al.
Publicado: (2016)

Immune Checkpoint Inhibitors in Peripheral T-Cell Lymphoma
por: Chen, Xi, et al.
Publicado: (2022)

Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumours
por: Brenner, Ellen, et al.
Publicado: (2020)

Angioimmunoblastic T-cell lymphoma associated with immune checkpoint inhibitor treatment
por: Duke, Taylor C., et al.
Publicado: (2020)

HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy?
por: Nijland, Marcel, et al.
Publicado: (2017)

Immune Checkpoint Inhibitors to Treat Malignant Lymphomas
por: Witkowska, Magdalena, et al.
Publicado: (2018)

Immune checkpoint inhibitors in lymphoma: challenges and opportunities
por: Hatic, Haris, et al.
Publicado: (2021)

T-cell lymphoma secondary to checkpoint inhibitor therapy
por: Anand, Kartik, et al.
Publicado: (2020)

EBV-gp350 Confers B-Cell Tropism to Tailored Exosomes and Is a Neo-Antigen in Normal and Malignant B Cells—A New Option for the Treatment of B-CLL
por: Ruiss, Romana, et al.
Publicado: (2011)

The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma
por: Meti, Nicholas, et al.
Publicado: (2018)

Immune checkpoint inhibitors in malignant lymphoma: Advances and perspectives
por: Lin, Ningjing, et al.
Publicado: (2020)

Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma
por: Ameli, Fereshteh, et al.
Publicado: (2022)

Targeted Therapies and Immune Checkpoint Inhibitors in Primary CNS Lymphoma
por: Wirsching, Hans-Georg, et al.
Publicado: (2021)

Mast Cells and Dendritic Cells as Cellular Immune Checkpoints in Immunotherapy of Solid Tumors
por: Kalkusova, Katerina, et al.
Publicado: (2022)

The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase‐positive non‐small cell lung cancer
por: Heo, Ja Yoon, et al.
Publicado: (2019)

Activating the Antitumor Immune Response in Non-Hodgkin Lymphoma Using Immune Checkpoint Inhibitors
por: Joshi, Maansi, et al.
Publicado: (2020)

Immune-related adverse events in the treatment of non-Hodgkin lymphoma with immune checkpoint inhibitors
por: Argnani, Lisa, et al.
Publicado: (2022)

Immune checkpoint inhibitors in renal cell carcinoma
por: Ross, Kirsty, et al.
Publicado: (2017)

Management of the Adverse Effects of Immune Checkpoint Inhibitors
por: Morgado, Manuel, et al.
Publicado: (2020)

Immune Checkpoint Molecules in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
por: Monabati, Ahmad, et al.
Publicado: (2020)

Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies
por: Hernandez, Carlos, et al.
Publicado: (2020)

Costimulatory Molecules and Immune Checkpoints Are Differentially Expressed on Different Subsets of Dendritic Cells
por: Carenza, Claudia, et al.
Publicado: (2019)

Checkpoint inhibitors in primary mediastinal B-cell lymphoma: a step forward in refractory/relapsing patients?
por: Balzarotti, Monica, et al.
Publicado: (2020)

Immune-Checkpoint Blockade Therapy in Lymphoma
por: Kuzume, Ayumi, et al.
Publicado: (2020)

Immune Checkpoint Inhibition in Hodgkin Lymphoma
por: Moy, Ryan H., et al.
Publicado: (2018)

Immune checkpoint inhibitors
por: Hui, Enfu
Publicado: (2019)

Immune checkpoint inhibitors
por: Kroemer, Guido, et al.
Publicado: (2021)

PD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to Allogeneic Dendritic Cells
por: Stecher, Carmen, et al.
Publicado: (2017)

Tumor Immune Microenvironment Components and Checkpoint Molecules in Anaplastic Variant of Diffuse Large B-Cell Lymphoma
por: Xu, Tianqi, et al.
Publicado: (2021)

B-cell lymphoma 2 inhibitor venetoclax treatment of a patient with cutaneous T-cell lymphoma
por: King, Amber Loren O., et al.
Publicado: (2020)

Immune-checkpoint inhibitors for combating T-cell dysfunction in cancer
por: Grywalska, Ewelina, et al.
Publicado: (2018)

Editorial: Immune checkpoint inhibitors in renal cell carcinoma
por: Tykodi, Scott S., et al.
Publicado: (2023)

Biomarkers for Immune Checkpoint Inhibitors in Renal Cell Carcinoma
por: Martin, Spencer D., et al.
Publicado: (2023)

Erratum to checkpoint inhibitors in primary mediastinal B-cell lymphoma: a step forward in refractory/relapsing patients?
por: Balzarotti, Monica, et al.
Publicado: (2020)

On the Other Side: Manipulating the Immune Checkpoint Landscape of Dendritic Cells to Enhance Cancer Immunotherapy
por: Kong, Benjamin Y., et al.
Publicado: (2019)

Diffuse large B-cell lymphoma (DLBCL) is infiltrated with activated CD8(+) T-cells despite immune checkpoint signaling
por: Greenbaum, Adam M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_v0qldrcuh9hiajg2t34dqkelu1